Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.47 |
| ▸ | YAP1 | P46937 | 3/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700986 | 1.00 | GPR119 (0.50) | GPR119PRMT5YAP1CHEK2 | |
| SCHEMBL2716908 | 0.89 | GPR119 (0.50) | GPR119PRMT5YAP1 | |
| SCHEMBL2716911 | 0.89 | GPR119 (0.50) | GPR119PRMT5YAP1 | |
| SCHEMBL2729944 | 0.87 | GPR119 (0.50) | GPR119PRMT5YAP1CHEK2 | |
| SCHEMBL2729942 | 0.87 | GPR119 (0.50) | GPR119PRMT5YAP1CHEK2 | |
| SCHEMBL2719056 | 0.87 | HRH3 (0.44) | PRMT5 | |
| SCHEMBL2718780 | 0.84 | GPR119 (0.47) | GPR119CHEK2 | |
| SCHEMBL2718781 | 0.84 | GPR119 (0.47) | GPR119CHEK2 | |
| SCHEMBL2730735 | 0.83 | GPR119 (0.53) | GPR119CHEK2 | |
| SCHEMBL2730737 | 0.83 | GPR119 (0.53) | GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | claimed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | claimed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | claimed |
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | disclosed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR4, GPR39 | GPR119 1/4885PRMT5 2940/4885YAP1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.